Source comparison
Melanotan 1 (MT1) vs. Similar Peptides: Side Effect Comparison
Comparing MT1's safety profile with related melanocortin analogs reveals important differences in tolerability and risk patterns. Melanotan 2 (MT2), the more widely studied analog, demonstrates higher rates of sexual side effects (20-30% vs. <5% for MT1) but s
This comparison does not assign a generated winner or score.
- Comparing MT1's safety profile with related melanocortin analogs reveals important differences in tolerability and risk patterns. Melanotan 2 (MT2), the more widely studied analog, demonstrates higher rates of sexual side effects (20-30% vs. <5% for MT1) but similar injection site reaction frequencies.[1]
- Melanotan 1 (MT1)
- MC1R agonist
- Injection site reactions (60-80%)
- 30-40% nausea
- 2-3% hypotension
- Minimal sexual effects
- Melanotan 2 (MT2)
- MC1R/MC4R agonist
- Injection site reactions (65-85%)
- 25-35% nausea
- 3-5% various
- Sexual dysfunction common
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist
- Nausea (40-50%)
- 40-55% GI effects
- 1-2% hypotension
- FDA-approved for HSDD
- α-MSH
- Natural MC1R agonist
- Minimal at physiologic doses
- <10% GI effects
- <1% serious events
- Shorter half-life, lower potency
- PT-141 (Bremelanotide), despite sharing melanocortin activity, shows higher gastrointestinal side effect rates (40-55%) but benefits from FDA approval and more extensive safety data from phase 3 trials involving over 1,200 patients. The peptide's indication for hypoactive sexual desire disorder provides a regulatory framework absent for MT1.
- Natural α-MSH demonstrates superior tolerability but requires more frequent dosing due to its 8-12 minute half-life compared to MT1's 30-45 minutes.[2] However, α-MSH's physiological role makes it less likely to cause unexpected adverse events, whereas MT1's synthetic modifications create theoretical risks not present with the natural hormone.